Department of Dermatology, Westmead Hospital, Sydney, NSW, Australia.
Lancet Oncol. 2013 Jan;14(1):e11-8. doi: 10.1016/S1470-2045(12)70413-8.
The RAF inhibitors vemurafenib and dabrafenib are emerging as the standard of care for Val600 BRAF-mutant metastatic melanoma. These drugs have shown clinical benefit over the standard care (dacarbazine); however, they are associated with frequent cutaneous adverse events, which can be concerning to the patient and their physician. Herein, we review the range of cutaneous disorders that seem to be induced by RAF inhibitors, including cutaneous squamous-cell carcinoma, hyperkeratotic lesions, Grover's disease, keratosis pilaris-like reactions, and photosensitivity. These disorders often affect patients' quality of life; therefore, dermatological assessment and timely management is essential to ensure that patients continue to use RAF inhibitors.
RAF 抑制剂威罗非尼和达拉非尼正成为 Val600BRAF 突变转移性黑色素瘤的标准治疗方法。这些药物在临床治疗上优于标准护理（达卡巴嗪）；然而，它们与频繁的皮肤不良事件有关，这可能会令患者及其医生感到担忧。在此，我们回顾了 RAF 抑制剂引起的一系列皮肤疾病，包括皮肤鳞状细胞癌、角化过度病变、Grover 病、毛发角化病样反应和光敏感性。这些疾病常常影响患者的生活质量；因此，皮肤科评估和及时管理对于确保患者继续使用 RAF 抑制剂至关重要。
